Background: Pruritus is very common symptom in patients under anti-cancer therapy. However, the characteristics of pruritus according to anti-cancer agents have not been known well. Objectives: To ascertain the characteristics of pruritus induced by targeted anti-cancer agents using a questionnaire-based survey. Methods: Questionnaires included numerical rating scale (NRS) for itching, 5-D itch scale and skin dryness. Medical records of anticancer treatment, including cancer types and types of anticancer agents, were reviewed. Results: Total 374 cancer patients finished the survey, of which 107 (28.6%) were treated with targeted therapy. Two hundreds and five (54.8%) patients had pruritus, of which 65 (31.7%) were under targeted therapy. Epidermal growth factor receptor inhibitors (EGFRIs) users showed highest prevalence of itching (77.3%) and score of NRS for itching. 5-D itch score was also highest in subjects of EGFRIs, particularly in items of duration, degree, disability and distribution. Patients of EGFRIs showed high prevalence of itching on face, chest, buttocks and upper arms. Skin dryness in EGFRIs showed strongest relationship with 5-D itch scale score. Conclusion: Patients receiving EGFRIs suffered from pruritus frequently and severely. They not only experienced long-lasting and intense itching causing sleep discomfort, also had specific body sites of itching. Clinicians should pay attention to unusual features of itching according to types of targeted therapy.